|
国际站:Sotatercept
CAS:1001080-50-7
品牌:MedChemExpress (MCE)
存储条件:Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性:Sotatercept (ACE-011) 是一种可溶性激活素受体 2A (ACVR2A) 型 IgG Fc 融合蛋白。Sotatercept 结合了激活素和生长分化因子,试图恢复生长促进和生长抑制信号通路之间的平衡。Sotatercept 在肺动脉高压、贫血、骨质流失、红细胞生成、多发性骨髓瘤 (MM) 溶骨性病变中有潜在的应用。
体外:Sotatercept (100 μg/mL) 下调了基质细胞分泌的 VEGF、抑瘤素 M (OSM)、IL-6、BMP-2、MMP-1 和 MMP13 表达水平[5]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献:[1]. Humbert M, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2021 Apr 1;384(13):1204-1215.[2]. Raje N, et al. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther. 2010 Oct;12(5):586-97.[3]. Abdulkadyrov KM, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014 Jun;165(6):814-23.[4]. Sherman ML, et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J Clin Pharmacol. 2013 Nov;53(11):1121-30.[5]. Iancu-Rubin C, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol. 2013 Feb;41(2):155-166.e17.
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-9-23 02:13
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社